Hide
Show all
Email this article Detection of Cerebellum Morphology during Experimental Post-Chemotherapy Cognitive Impairment (PCCI)
Abstract
Background: Multiple animal studies and clinical investigations have stated are accompanied with Post-Chemotherapy Cognitive Impairment (PCCI), and was proposed several possible underlying mechanisms contributing to PCCI, but exact structural basis is still not well defined.
Aim: Examine the effects of doxorubicin (DOX) on the cerebellum, which would enable us to contribute to the definition of the functional and molecular mechanisms of DOX-induced neurotoxicity.
Methods: The experiment was conducted on four groups of rats, which were administered DOX in different doses, which studied histologically and immunohistochemically investigated.
Results: The study reveals disorders of cerebellum layers, especially Purkinje cell layer, starting from various degrees neuronal damage, dystrophic-degenerative processes, and chromatolysis to total disintegration and reactive astrocytosis, with clear association between DOX effect and cerebellar pathology.
Conclusion: The research database of doxorubicin (DOX) effectsshowed significant changes with a large range of destruction in the cytoarchitecture of the cerebellum. These changes in all neuronal elements can be considered as an essential basis for post-chemotherapy cognitive impairment.
Keywords
Full Text:
PDFReferences
Ahles T.A. Brain vulnerability to chemotherapy toxicities. Psycho-Oncology 2012, 21, 1141–1148.
F. Joly,B. Giffard, O. Rigal, M.B. DeRuiter, B.J. Small, M. Dubois, J. LeFel, S.B. Schagen, T.A. Ahles, J.S. Wefel, J.L. Vardy, V. Pancré, M. Lange, H. Castel - Impact of cancer and its treatments on cognitive function: advances in research from the Paris international cognition and cancer task force symposium and update since 2012,J. Pain. Symptoms. Management. 2015, 50 (6), pp. 830-841.
Bernstein J., Edelstein K., Sharma A. - Chemo-brain: An activation likelihood estimation meta-analysis of functional magnetic resonance imaging studies. Neuroscience & Biobehavioral Reviews. 2021, 11, Vol.130: 314-325.
V.Rao, R.Bhushan, P.Kumari, S.P. Cheruku, V. Ravichandiran, N.Kumar – Chapter Two – Chemobrain: A review on mechanistic insight, targets and treatments. Advances in Cancer Research. 2022, V.155:29-76.
R. Zajączkowska, M. KocotKępska, W. Leppert, A. Wrzosek, J. Mika, J. Wordliczek - Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci.,2019, 20 (6), 1451.
Koppelmans V., Breteler M. M., Boogerd W., Seynaeve C., Gundy, C., Schagen S. B. - Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J. Clin. Oncol. 2012, 30, pp. 1080–1086.
K. Moore, S. Stutzman, L. Priddy, D. Olson - Chemobrain: a pilot study exploring the severity and onset of chemotherapy-related cognitive impairment. Clin. J. Oncol. Nurs.,2019, 23 (4): 411-416.
L.C. Murillo, J.J. Sutachan, S.L. Albarracín -An update on neurobiological mechanisms involved in the development of chemotherapy-induced cognitive impairment (CICI);Toxicology Reports, 2023, vol.10, 544-553.
D.D. Shi, Y.H. Huang, C.S.W. Lai, C.M. Dong, L.C. Ho, E.X. Wu, Q. Li, X.,M. Wang, S.K. Chung, P.C. Sham, Z.-J. Zhang - Chemotherapy-induced cognitive impairment is associated with cytokine dysregulation and disruptions in neuroplasticity, Mol. Neurobiol., 2019, 56 (3), pp. 2234-2243.
Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, Wada N, Imoto S, Murakami K, Uchitomi Y: Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007, 109: 146-156.
Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddel Petersen L, Phelps MR, Ganz PA: Altered frontocortical, cerebellar and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007, 103: 303-311.
Han R, Yang YM, Dietrich J, Luebke A, Mayer-Pröschel M, Noble M: Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol. 2008, 7: 12-10.
Cacho-Díaz, Bernardo, Lorenzana-Mendoza N., Salmerón-Moreno K., Reyes-Soto, Gervith M., Castillo-Rangel C., Corona-Cedillo R., Escobar-Ceballos S., Garza-Salazar J.- Chemotherapy-induced posterior reversible encephalopathy syndrome. Three case reports. Medicine. 2019, May, 98(19):p e15691.
Yang Liu, Dennis Chang, Tianqing Liu, Xian Zhou- Natural product-based bioactive agents in combination attenuate neuroinflammation in a tri-culture model. Front Pharmacology. 2023; 14: 1135934.
F.H. Shaker, M.O. El-Derany, S.A. Wahdan, E. El-Demerdash, H.O. El-Mesallamy - Berberine ameliorates doxorubicin-induced cognitive impairment (chemobrain) in rats; Life Sci., 2021, 269, Article 119078.
S.A. Wahdan, M.O. El-Derany, A.E. Abdel-Maged, S.S. Azab - Abrogating doxorubicin-induced chemobrain by immunomodulators IFN-beta 1a or infliximab: Insights to neuroimmune mechanistic hallmarks; Neurochem. Int., 2020, 138, Article 104777.
A.H.Alhowail, J. Bloemer, M. Majrashi, P.D. Pinky, S. Bhattacharya, Z. Yongli, D. Bhattachary, M. Eggert, L. Woodie, M.A. Buabeid, N. Johnson, A. Broadwater, B. Smith, M. Dhanasekaran, R.D. Arnold, V. Suppiramaniam- Doxorubicin-induced neurotoxicity is associated with acute alterations in synaptic plasticity, apoptosis, and lipid peroxidation; Toxicol. Mech. Methods, 2019, 29 (6),457-466.
C. Wang, Y. Zhao, L. Wang, S. Pan, Y. Liu, S. Li, D. Wang -C-phycocyanin mitigates cognitive impairment in doxorubicin-induced chemobrain: impact on neuroinflammation, oxidative stress, and brain mitochondrial and synaptic alterations; Neurochem. 2021, 46 (2); 149-158.
J. Flanigan, J.E. Anderson, I. Elayan, A.R. Allen, S.A. Ferguson - Effects of cyclophosphamide and/or doxorubicin in a murine model of postchemotherapy cognitive impairment; Toxicol. Sci., 2018, 162 (2), 462-474.
C.D. Aluise, R.Sultana, J.Tangpong, M.Vore, D.St.Clair, -Chemo Brain (Chemo Fog) as a Potential Side Effect of Doxorubicin Administration: Role of Cytokine-Induced, Oxidative/Nitrosative Stress in Cognitive Dysfunction Neuroscience, 2011, 147–156.
J.S. Myers, J. Pierce, T. Pazdernik: Neurotoxicology of chemotherapy in relation to cytokine release, the blood-brain barrier, and cognitive impairment. Oncol. Nurs. Forum, 2008, 35 (6): 916-920.
Buffo A., Rite I., Tripathi P., Lepier A., Colak D., Horn A.-P., Mori T., Götz M. - Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain // PNAS. 2008. Vol. 105, N9; 3581– 3586.
C. Pellacani, G. Eleftheriou - Neurotoxicity of antineoplastic drugs: mechanisms, susceptibility, and neuroprotective strategies. Adv. Med. Sci., 2020, 65 (2) 265-285.
Pozhilov D.A., Rumyantseva T.A., Nakibulla D.A., Agadzhanova L.S. – Response of astrocytic glia to acute neurotoxic effect in rats of different ages – J. of New medical Technilogies, 2022, vol. 29 (3), 78-82.
C.V.Cardoso, M.Paes deBarros, A.L.Lacerda Bachi, M.M.Bernardi, Th.B.Kirsten, M.F.Monteiro Martins, P.R.Dell’Armelina Rocha, P.S.Rodrigues, E. F.Bondan -Chemobrain in rats: Behavioral, morphological, oxidative and inflammatory effects of doxorubicin administration. Behavioral Brain Research, 2020, Vol.378, N1; 11233.
Freeman MR. - Specification and morphogenesis of astrocytes. Science. 2010. Vol. 330, N6005; 774–778.
M.Pekny, M.Pekne - Reactive gliosis in the pathogenesis of CNS diseases. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2016, vol.1862, 3; 483-491.
Zhihui Yang , Kevin K W Wang - Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker; Trends Neurosci. 2015 Jun;38(6):364-74.
Refbacks
- There are currently no refbacks.
ISSN: 2346-8491 (online)